Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial (Q33604322)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial (English)

1 reference

Europe PubMed Central

28 July 2017

0 references

1 reference

based on heuristic

inferred from title

abacavir/lamivudine

1 reference

based on heuristic

inferred from title

object named as

Mark S Shaefer

10

0 references

author name string

David A Wohl

1

1 reference

Europe PubMed Central

28 July 2017

Laveeza Bhatti

2

1 reference

Europe PubMed Central

28 July 2017

Catherine B Small

3

1 reference

Europe PubMed Central

28 July 2017

Howard Edelstein

4

1 reference

Europe PubMed Central

28 July 2017

Henry H Zhao

5

1 reference

Europe PubMed Central

28 July 2017

David A Margolis

6

1 reference

Europe PubMed Central

28 July 2017

Edwin DeJesus

7

1 reference

Europe PubMed Central

28 July 2017

Winkler G Weinberg

8

1 reference

Europe PubMed Central

28 July 2017

Lisa L Ross

9

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

13 May 2014

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

9

1 reference

Europe PubMed Central

28 July 2017

5

1 reference

Europe PubMed Central

28 July 2017

e96187

1 reference

Europe PubMed Central

28 July 2017

copyright license

Creative Commons Attribution 4.0 International

13 May 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Update of the drug resistance mutations in HIV-1: March 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

21 June 2018

Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019479

30 October 2018

Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096187

21 January 2018

Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used

1 reference

https://pubmed.ncbi.nlm.nih.gov/24825167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0096187

1 reference

Europe PubMed Central

28 July 2017

2014PLoSO...996187W

0 references

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33604322&oldid=1861785282"